|
| Press Releases |
|
 |
|
| Tuesday, July 27, 2021 |
|
|
Biogen and Eisai Announce ADUHELM (aducanumab-avwa) Data Presentations at Alzheimer's Association International Conference 2021 |
| Biogen (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced that Biogen, as part of its Alzheimer's disease (AD) research portfolio, will contribute four virtual posters that showcase data from its clinical trials with ADUHELMTM (aducanumab-avwa) injection 100 mg/mL solution at the AAIC. more info >> |
|
| Friday, July 23, 2021 |
|
|
Eisai: FDA Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination for Patients With Certain Types of Advanced Endometrial Carcinoma |
| Study Results Demonstrated Statistically Significant Improvements in Overall Survival, Progression-Free Survival and Overall Response Rate, Helping to Address a Significant Unmet Need in Advanced Endometrial Carcinoma. more info >> |
|
| Wednesday, July 21, 2021 |
|
|
Eisai to Present Latest Data on Pipeline Assets in The Area of Alzheimer's Disease and Dementia at AAIC 2021 |
| Eisai Co., Ltd. announced today that the company will conduct a total of 11 presentations, including the latest data of the investigational anti-amyloid beta (Abeta) protofibril antibody lecanemab (development code: BAN2401) for which the U.S. Food and Drug Administration has granted Breakthrough Therapy designation, at the Alzheimer's Association International Conference (AAIC). more info >> |
|
| Monday, July 19, 2021 |
|
|
Eisai Launchs Bile Acid Transporter Inhibitor Goofice in Thailand |
| Eisai Co., Ltd. announced that its Thailand subsidiary Eisai (Thailand) Marketing Co., Ltd. has launched the bile acid transporter inhibitor Goofice (generic name: elobixibat hydrate) in Thailand. more info >> |
|
| Thursday, July 1, 2021 |
|
|
Eisai Launches In-house Developed Anti-insomnia Drug Dayvigo (Lemborexant) In Hong Kong |
| Eisai Co., Ltd. announced today that its Hong Kong subsidiary Eisai (Hong Kong) Co., Ltd. has launched the in-house-discovered and developed orexin receptor antagonist DAYVIGO (generic name: lemborexant) for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. more info >> |
|
| Thursday, June 24, 2021 |
|
|
Eisai and Biogen Inc. Announce U.S. FDA Grants Breakthough Therapy Designation for Lecanemab (BAN2401) |
| Eisai Co., Ltd. and Biogen Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthough Therapy designation for lecanemab (BAN2401), an investigational anti-amyloid beta (Abeta) protofibril antibody for the treatment of Alzheimer's disease (AD). more info >> |
|
| Wednesday, June 23, 2021 |
|
|
Anticancer Agent "Tazverik Tablets 200mg" (Tazemetostat Hydrobromide) Approved In Japan For EZH2 Gene Mutation-positive Follicular Lymphoma |
| Eisai Co., Ltd. announced today that it has obtained manufacturing and marketing approval for the EZH2 inhibitor "Tazverik Tablets 200 mg" (tazemetostat hydrobromide) in Japan with the indication of relapsed or refractory EZH2 gene mutation-positive follicular lymphoma (only when standard treatment is not applicable). more info >> |
|
| Friday, June 18, 2021 |
|
|
Eisai, Bristol Myers Squibb Enter Into Global Strategic Collaboration for Eisai's MORAb-202 Antibody Drug Conjugate |
| Eisai Co., Ltd. and Bristol-Myers Squibb Company announced today that the companies have entered into an exclusive global strategic collaboration agreement for the co-development and co-commercialization of MORAb-202, an antibody drug conjugate (ADC). more info >> |
|
| Tuesday, June 15, 2021 |
|
|
Eisai to Divest Rights for Zonegran in Europe and Other Regions to Advanz Pharma |
| Eisai Co., Ltd. announced today that it has entered into an agreement to divest its rights for the antiepileptic agent Zonegran (generic name: zonisamide) in Europe, the Middle East, Russia, and Australia to Advanz Pharma. more info >> |
|
| Wednesday, June 9, 2021 |
|
|
Eisai Receives Special Prize at Platinum Career Award 2021 |
| Eisai Co., Ltd. announced today that it has received a special prize at the Platinum Career Award 2021. The awards ceremony was held via online at the symposium on June 8, 2021. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Champion REIT Presents 'Lupus Reimagined' Art Exhibition, Connecting Community Through Art 
Jun 6, 2025 22:35 HKT/SGT
|
|
|
International Consortium Rolls Out Major EV Battery Swapping Initiative in Tokyo
Jun 6, 2025 16:42 JST
|
|
|
Tredu.com Launches Global Platform to Revolutionize Trading Education
Jun 6, 2025 15:40 HKT/SGT
|
|
|
TANAKA PRECIOUS METAL TECHNOLOGIES Receives 2025 Technology Award from Catalyst Manufacturers Association, Japan, for Development and Practical Application of Electrode Catalysts for PEM Water Electrolysis
Jun 6, 2025 11:00 JST
|
|
|
Fujitsu unveils Technology and Service Vision 2025: People-AI collaboration for a net positive future
Jun 6, 2025 10:44 JST
|
|
|
Latest Firewall Vulnerability Reinforces Need for Post-Breach Privileged Access Controls - TACACS.net Offers a Critical Layer
Jun 6, 2025 04:30 HKT/SGT
|
|
|
Naoris Protocol Expands into the Nordics with Strategic Consulting Hub in Oslo
Jun 5, 2025 21:00 HKT/SGT
|
|
|
PlayX Showcases AI-Powered Transparency and Fairness at SiGMA Asia 2025 in Manila
Jun 5, 2025 17:00 HKT/SGT
|
|
|
The Generation Essentials Group and Black Spade Acquisition II Co Complete Business Combination
Jun 5, 2025 11:33 HKT/SGT
|
|
|
Global Communities Unite at centralwOrld as Thailand Steps Forward on Global LGBTQ+ Stage with Central Pattana's Pride For All
Jun 5, 2025 08:30 HKT/SGT
|
|
|
TF International Facilitates Hong Kong's Successful Issuance of First Central Asian Sovereign Bond
Jun 4, 2025 22:28 HKT/SGT
|
|
|
Alpha Growth plc: Alpha Alternative Assets Fund Update ("AAAF")
Jun 4, 2025 15:00 JST
|
|
|
MHI Thermal Systems Receives A' Design Awards
Jun 4, 2025 14:10 JST
|
|
|
CBL International Limited Announces Share Repurchase Program
Jun 4, 2025 12:00 HKT/SGT
|
|
|
Orange completes successful trial of Fujitsu 1FINITY optical transport solution
Jun 4, 2025 12:58 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
